2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies

BACKGROUND: Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated extraordinary efficacy in B cell malignancy therapy and have been approved by the US Food and Drug Administration for diffuse large B cell lymphoma and acute B lymphocytic leukemia treatment. However, treatment of T c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Xu, Yingxi, Liu, Qian, Zhong, Mengjun, Wang, Zhenzhen, Chen, Zhaoqi, Zhang, Yu, Xing, Haiyan, Tian, Zheng, Tang, Kejing, Liao, Xiaolong, Rao, Qing, Wang, Min, Wang, Jianxiang
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6524286/
https://ncbi.nlm.nih.gov/pubmed/31097020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0732-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados